Comparative Efficacy of 14 Chinese Patent Medicines for Heart Disease with Diabetes

A systematic review and network meta-analysis of 71 randomized controlled trials involving 7,988 patients with coronary heart disease complicated by diabetes. The dataset, authored by Dan Han and last updated in 2026, compares the efficacy and safety of 14 oral Chinese patent medicines combined with conventional Western therapy. It evaluates outcomes including glycemic control, lipid profiles, cardiac function, angina, inflammatory markers, and adverse events.

Use Cases

• Ranking treatment efficacy for specific outcomes like triglyceride reduction based on network meta-analysis results.
• Analyzing the relationship between different Chinese patent medicines and cardiac function parameters such as left ventricular ejection fraction.
• Comparing the safety profiles of adjunctive therapies by examining reported adverse reaction data.
• Identifying optimal treatment combinations for glycemic control metrics like HbA1c and fasting blood glucose.

Strengths

• Includes data from 71 randomized controlled trials, a substantial evidence base for meta-analysis.
• Covers a total sample size of 7,988 patients across the included studies.
• Evaluates a wide range of 14 different oral Chinese patent medicines.
• Assesses multiple outcome domains including clinical efficacy, laboratory markers, and safety.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic or publication bias inherent to the included Chinese and international databases.

Provenance

Source

figshare, author Dan Han.

Collection Method

Systematic review and network meta-analysis of randomized controlled trials.

Freshness

Last updated 2026-04-30 04:18:14; freshness should be verified.

Geography

Studies likely conducted primarily in China, based on the focus of the therapies.